{
  "run": {
    "id": "cmnr12kte02gsp658db6tryyl",
    "region": "US",
    "assetId": "cmnr12ksw02ghp658asvo8db2",
    "ticker": "BMY",
    "snapshotId": "cmnr12kt702glp6580vozvdfk",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:19:50.495Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr12kt702glp6580vozvdfk",
      "assetId": "cmnr12ksw02ghp658asvo8db2",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 59.2,
          "dayLow": 57.67,
          "volume": 8926108,
          "dayHigh": 59.23,
          "currency": "USD",
          "prevClose": 57.67,
          "week52Low": 42.52,
          "week52High": 62.89
        },
        "fundamentals": {
          "pe": 15.5446685878963,
          "beta": 0.297203048701022,
          "epsTTM": 3.47,
          "fcfTTM": 9738000000,
          "growth": {
            "epsYoy": 1.786848072562358,
            "revenueYoy": -0.002194616977225673
          },
          "sector": "Pharmaceutical Preparations",
          "margins": {
            "net": -0.2120278470294934,
            "gross": 0.7231055082553272,
            "operating": null
          },
          "website": "http://bms.com",
          "industry": "Pharmaceuticals",
          "pegRatio": -0.0869949092292163,
          "ebitdaTTM": 16220000000,
          "forwardPe": 8.65810593900481,
          "marketCap": 94188864457,
          "totalCash": 10209000000,
          "totalDebt": 47088000000,
          "debtEquity": 2.54901748497808,
          "quickRatio": 0.9432036554639791,
          "revenueTTM": 42518000000,
          "companyName": "BRISTOL MYERS SQUIBB CO",
          "priceToBook": 5.92888192380438,
          "currentRatio": 1.255071102190716,
          "dividendYield": 0.0459832094293197,
          "returnOnAssets": -0.1001243919234101,
          "returnOnEquity": 0.381854598603367,
          "analystOpinions": null,
          "businessSummary": "Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelody…",
          "enterpriseValue": 146592960000,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 32500,
          "sharesOutstanding": 2036473705,
          "enterpriseToEbitda": 9.037790382244143,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 3.447785878921868,
          "operatingCashflowTTM": 14156000000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:19:50.491Z"
    },
    "results": [
      {
        "id": "cmnr12ktg02gup658nmgeo1v5",
        "runId": "cmnr12kte02gsp658db6tryyl",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BMY\",\"currency\":\"USD\",\"current_price\":59.2,\"target_price_6m\":62.5,\"target_price_12m\":65.0,\"recommendation\":\"BUY\",\"confidence\":0.60,\"thesis_bullets\":[\"Attractive forward P/E of ~8.7x signals deep value vs pharma peers\",\"Strong FCF of ~$9.7B supports 4.6% dividend and deleveraging\",\"New growth assets (Cobenfy, Camzyos, Opdualag) ramping to offset cliffs\",\"Eliquis patent cliff (~2028) remains the dominant medium-term overhang\",\"High leverage at 2.5x debt/equity constrains strategic flexibility\"],\"key_drivers\":[{\"driver\":\"Eliquis patent cliff timeline and generic erosion pace\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Cobenfy (KarXT) commercial launch trajectory in schizophrenia\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Opdivo franchise durability and label expansions\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction progress from strong free cash flow\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Camzyos uptake in hypertrophic cardiomyopathy\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Reblozyl and Sotyktu growth contributions\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline clinical readouts and regulatory decisions\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing pressure from IRA Medicare drug negotiation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Macro tariff/trade policy impact on supply chain costs\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Eliquis generics arrive earlier or erode revenue faster than modeled\",\"Cobenfy launch disappoints on uptake, safety signals, or payer pushback\",\"Total debt of $47B limits M&A optionality and raises refinancing risk\",\"IRA drug price negotiations compress margins on key brands\",\"Pipeline clinical failures reduce long-term revenue replacement capacity\",\"Competitive biosimilar/generic threats to Opdivo and Revlimid residual sales\"],\"assumptions\":{\"revenue_cagr_3y\":0.02,\"ebit_margin_target\":0.32,\"wacc\":0.085,\"terminal_multiple\":9.5},\"scenarios\":{\"bear\":{\"target_price\":48.0,\"prob\":0.20,\"notes\":\"Accelerated Eliquis erosion and Cobenfy launch misses; earnings decline.\"},\"base\":{\"target_price\":65.0,\"prob\":0.55,\"notes\":\"Orderly patent cliff transition; new products ramp as guided; steady FCF.\"},\"bull\":{\"target_price\":76.0,\"prob\":0.25,\"notes\":\"New launches exceed expectations; pipeline catalysts drive re-rating above 11x forward earnings.\"}},\"method_notes\":\"Blended valuation: forward P/E (8.7x on ~$6.8 fwd EPS) and EV/EBITDA (9x) vs pharma peers (10-12x). Applied 9.5x terminal EV/EBITDA on normalized EBITDA ~$17B, net debt adjusted. 12M target of $65 implies ~9.8% total return (incl ~4.6% div yield), supporting BUY. Confidence at 0.60 reflects material patent cliff uncertainty partially offset by strong FCF and cheap valuation. Sell-side targets noted in ~$55-70 range but not used as numeric input. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Eliquis generics arrive earlier or erode revenue faster than modeled",
            "Cobenfy launch disappoints on uptake, safety signals, or payer pushback",
            "Total debt of $47B limits M&A optionality and raises refinancing risk",
            "IRA drug price negotiations compress margins on key brands",
            "Pipeline clinical failures reduce long-term revenue replacement capacity",
            "Competitive biosimilar/generic threats to Opdivo and Revlimid residual sales"
          ],
          "ticker": "BMY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Orderly patent cliff transition; new products ramp as guided; steady FCF.",
              "target_price": 65
            },
            "bear": {
              "prob": 0.2,
              "notes": "Accelerated Eliquis erosion and Cobenfy launch misses; earnings decline.",
              "target_price": 48
            },
            "bull": {
              "prob": 0.25,
              "notes": "New launches exceed expectations; pipeline catalysts drive re-rating above 11x forward earnings.",
              "target_price": 76
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.02,
            "terminal_multiple": 9.5,
            "ebit_margin_target": 0.32
          },
          "key_drivers": [
            {
              "driver": "Eliquis patent cliff timeline and generic erosion pace",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Cobenfy (KarXT) commercial launch trajectory in schizophrenia",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Opdivo franchise durability and label expansions",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Debt reduction progress from strong free cash flow",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Camzyos uptake in hypertrophic cardiomyopathy",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Reblozyl and Sotyktu growth contributions",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pipeline clinical readouts and regulatory decisions",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pricing pressure from IRA Medicare drug negotiation",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Macro tariff/trade policy impact on supply chain costs",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended valuation: forward P/E (8.7x on ~$6.8 fwd EPS) and EV/EBITDA (9x) vs pharma peers (10-12x). Applied 9.5x terminal EV/EBITDA on normalized EBITDA ~$17B, net debt adjusted. 12M target of $65 implies ~9.8% total return (incl ~4.6% div yield), supporting BUY. Confidence at 0.60 reflects material patent cliff uncertainty partially offset by strong FCF and cheap valuation. Sell-side targets noted in ~$55-70 range but not used as numeric input. Not investment advice.",
          "current_price": 59.2,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Attractive forward P/E of ~8.7x signals deep value vs pharma peers",
            "Strong FCF of ~$9.7B supports 4.6% dividend and deleveraging",
            "New growth assets (Cobenfy, Camzyos, Opdualag) ramping to offset cliffs",
            "Eliquis patent cliff (~2028) remains the dominant medium-term overhang",
            "High leverage at 2.5x debt/equity constrains strategic flexibility"
          ],
          "target_price_6m": 62.5,
          "target_price_12m": 65
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 39979,
        "createdAt": "2026-04-09T05:19:50.495Z",
        "usage": {
          "inputTokens": 3791,
          "outputTokens": 1882,
          "costUsd": 0.066005
        }
      },
      {
        "id": "cmnr12ktg02gxp658nm8z6ere",
        "runId": "cmnr12kte02gsp658db6tryyl",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Pharma DCF and Multiples Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"BMY\",\n  \"currency\": \"USD\",\n  \"current_price\": 59.2,\n  \"target_price_6m\": 60.0,\n  \"target_price_12m\": 62.0,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"Diversified portfolio with key blockbuster drugs driving revenue.\",\n    \"Significant patent expirations pose near-term revenue risks.\",\n    \"R&D pipeline offers potential for long-term growth opportunities.\",\n    \"Strong cash flow supports dividend stability and debt reduction.\",\n    \"Current valuation reflects a balanced risk-reward profile.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"Eliquis revenue growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Opdivo market expansion\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Patent expirations impact\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n    { \"driver\": \"New drug approvals from pipeline\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Cost efficiency improvements\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Debt reduction progress\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Regulatory environment stability\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Dividend yield attractiveness\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n  ],\n  \"risks\": [\"Accelerated patent losses\", \"Clinical trial failures\", \"Increased generic competition\", \"Regulatory setbacks\", \"Economic downturn impact\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.02,\n    \"ebit_margin_target\": 0.20,\n    \"wacc\": 0.08,\n    \"terminal_multiple\": 10.0\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 50.0, \"prob\": 0.2, \"notes\": \"Worse-than-expected patent impacts and sales decline.\" },\n    \"base\": { \"target_price\": 62.0, \"prob\": 0.6, \"notes\": \"Steady performance with modest growth and cost control.\" },\n    \"bull\": { \"target_price\": 70.0, \"prob\": 0.2, \"notes\": \"Strong pipeline successes driving above-expected revenue growth.\" }\n  },\n  \"method_notes\": \"Valuation based on DCF with 2% revenue CAGR and 20% EBIT margin; HOLD due to 4.7% expected upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Pharma DCF and Multiples Model",
          "risks": [
            "Accelerated patent losses",
            "Clinical trial failures",
            "Increased generic competition",
            "Regulatory setbacks",
            "Economic downturn impact"
          ],
          "ticker": "BMY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady performance with modest growth and cost control.",
              "target_price": 62
            },
            "bear": {
              "prob": 0.2,
              "notes": "Worse-than-expected patent impacts and sales decline.",
              "target_price": 50
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong pipeline successes driving above-expected revenue growth.",
              "target_price": 70
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.02,
            "terminal_multiple": 10,
            "ebit_margin_target": 0.2
          },
          "key_drivers": [
            {
              "driver": "Eliquis revenue growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Opdivo market expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Patent expirations impact",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "New drug approvals from pipeline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Cost efficiency improvements",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt reduction progress",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Regulatory environment stability",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Dividend yield attractiveness",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on DCF with 2% revenue CAGR and 20% EBIT margin; HOLD due to 4.7% expected upside. Not investment advice.",
          "current_price": 59.2,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Diversified portfolio with key blockbuster drugs driving revenue.",
            "Significant patent expirations pose near-term revenue risks.",
            "R&D pipeline offers potential for long-term growth opportunities.",
            "Strong cash flow supports dividend stability and debt reduction.",
            "Current valuation reflects a balanced risk-reward profile."
          ],
          "target_price_6m": 60,
          "target_price_12m": 62
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 571,
        "createdAt": "2026-04-09T05:19:50.495Z",
        "usage": {
          "inputTokens": 2265,
          "outputTokens": 3525,
          "costUsd": 0.002115
        }
      },
      {
        "id": "cmnr12ktg02gvp6585tmv0ofp",
        "runId": "cmnr12kte02gsp658db6tryyl",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"EquityResearch-Pro-v1\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"BMY\",\n  \"currency\": \"USD\",\n  \"current_price\": 59.2,\n  \"target_price_6m\": 63.0,\n  \"target_price_12m\": 66.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"BMY trades at a depressed 8.7x forward P/E, pricing in severe LOE cliff risks.\",\n    \"Strong FCF generation of $9.7B comfortably supports the attractive 4.6% dividend yield.\",\n    \"New product portfolio is ramping up steadily to offset Revlimid generic erosion.\",\n    \"Recent acquisitions bolster the mid-to-late stage pipeline, though integration risks remain.\",\n    \"Heavy debt load of $47B limits near-term M&A flexibility and aggressive share repurchases.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Eliquis and Opdivo LOE timeline\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"New product portfolio revenue ramp\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"KarXT (Cobenfy) commercial launch success\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Strong free cash flow generation\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"High debt-to-equity ratio\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Dividend yield support\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"IRA Medicare price negotiation impacts\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Faster-than-expected revenue erosion from Revlimid, Eliquis, and Opdivo generics.\",\n    \"Failure of newly acquired pipeline assets to meet peak sales estimates.\",\n    \"Regulatory and pricing pressures from the US Inflation Reduction Act (IRA).\",\n    \"High leverage ratio restricting future capital allocation and dividend growth.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.015,\n    \"ebit_margin_target\": 0.35,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 9.0\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 50.0,\n      \"prob\": 0.25,\n      \"notes\": \"New products fail to offset LOE cliffs, margins compress under pricing pressure.\"\n    },\n    \"base\": {\n      \"target_price\": 66.0,\n      \"prob\": 0.5,\n      \"notes\": \"New portfolio ramps as expected, stabilizing revenues and supporting debt paydown.\"\n    },\n    \"bull\": {\n      \"target_price\": 82.0,\n      \"prob\": 0.25,\n      \"notes\": \"Pipeline assets exceed expectations, driving multiple expansion and renewed growth.\"\n    }\n  },\n  \"method_notes\": \"Valuation based on a 10-year DCF and EV/EBITDA multiples. Base case implies an 11.5% upside, supporting a BUY rating. Probability-weighted scenario target is $66.00. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "EquityResearch-Pro-v1",
          "risks": [
            "Faster-than-expected revenue erosion from Revlimid, Eliquis, and Opdivo generics.",
            "Failure of newly acquired pipeline assets to meet peak sales estimates.",
            "Regulatory and pricing pressures from the US Inflation Reduction Act (IRA).",
            "High leverage ratio restricting future capital allocation and dividend growth."
          ],
          "ticker": "BMY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "New portfolio ramps as expected, stabilizing revenues and supporting debt paydown.",
              "target_price": 66
            },
            "bear": {
              "prob": 0.25,
              "notes": "New products fail to offset LOE cliffs, margins compress under pricing pressure.",
              "target_price": 50
            },
            "bull": {
              "prob": 0.25,
              "notes": "Pipeline assets exceed expectations, driving multiple expansion and renewed growth.",
              "target_price": 82
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.015,
            "terminal_multiple": 9,
            "ebit_margin_target": 0.35
          },
          "key_drivers": [
            {
              "driver": "Eliquis and Opdivo LOE timeline",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "New product portfolio revenue ramp",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "KarXT (Cobenfy) commercial launch success",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Strong free cash flow generation",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "High debt-to-equity ratio",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Dividend yield support",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "IRA Medicare price negotiation impacts",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on a 10-year DCF and EV/EBITDA multiples. Base case implies an 11.5% upside, supporting a BUY rating. Probability-weighted scenario target is $66.00. Not investment advice.",
          "current_price": 59.2,
          "recommendation": "BUY",
          "thesis_bullets": [
            "BMY trades at a depressed 8.7x forward P/E, pricing in severe LOE cliff risks.",
            "Strong FCF generation of $9.7B comfortably supports the attractive 4.6% dividend yield.",
            "New product portfolio is ramping up steadily to offset Revlimid generic erosion.",
            "Recent acquisitions bolster the mid-to-late stage pipeline, though integration risks remain.",
            "Heavy debt load of $47B limits near-term M&A flexibility and aggressive share repurchases."
          ],
          "target_price_6m": 63,
          "target_price_12m": 66
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.",
              "attempt": 0,
              "rawOutputTruncated": "{\n  \"model\": \"EquityResearch-Pro-v1\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"BMY\",\n  \"currency\": \"USD\",\n  \"current_price\": 59.2,\n  \"target_price_6m\": 62.0,\n  \"target_price_12m\": 65.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"BMY trades at a depressed 8.7x forward P/E, pricing in severe LOE cliff risks.\",\n    \"Strong FCF generation of $9.7B comfortably supports the attractive 4.6% dividend yield.\",\n    \"New product portfolio is ramping up steadily to offset Revlimid generic erosion.\",\n    \"Recent acquisitions bolster the mid-to-late stage pipeline, though integration and execution risks remain.\",\n    \"Heavy debt load of $47B limits near-term M&A flexibility and aggressive share repurchases.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Eliquis and Opdivo LOE timeline\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"New product portfolio revenue ramp\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"KarXT (Cobenfy) commercial launch success\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Strong free cash flow generation\",\n      \"impact\": \"M…"
            }
          ],
          "providerMeta": {
            "model": "gemini-3-pro-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 22796,
        "createdAt": "2026-04-09T05:19:50.495Z",
        "usage": {
          "inputTokens": 3331,
          "outputTokens": 895,
          "costUsd": 0.017402
        }
      },
      {
        "id": "cmnr12ktg02gtp6588f37olv3",
        "runId": "cmnr12kte02gsp658db6tryyl",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BMY\",\"currency\":\"USD\",\"current_price\":59.2,\"target_price_6m\":60.9,\"target_price_12m\":62,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward valuation looks inexpensive for a large-cap pharma franchise.\",\"Strong cash flow and dividend provide downside support.\",\"Revlimid erosion still offsets much of newer product growth.\",\"Pipeline and launches can stabilize revenue, but visibility is mixed.\",\"Leverage and patent-cliff risk limit multiple expansion.\"],\"key_drivers\":[{\"driver\":\"New product uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Revlimid generic erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Eliquis franchise durability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Opdivo growth and labels\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction pace\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline readouts\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Drug-pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Pipeline failures or delays\",\"Faster generic or biosimilar erosion\",\"US pricing and IRA pressure\",\"Higher leverage reduces flexibility\"],\"assumptions\":{\"revenue_cagr_3y\":0.012,\"ebit_margin_target\":0.34,\"wacc\":0.082,\"terminal_multiple\":8.8},\"scenarios\":{\"bear\":{\"target_price\":50,\"prob\":0.25,\"notes\":\"Legacy erosion and weak pipeline execution drive de-rating.\"},\"base\":{\"target_price\":62,\"prob\":0.5,\"notes\":\"Cash flow stays solid while newer brands partly offset LOE pressure.\"},\"bull\":{\"target_price\":72,\"prob\":0.25,\"notes\":\"Pipeline wins and launch traction support modest re-rating.\"}},\"method_notes\":\"Used snapshot quote/fundamentals exactly. 12M target is a blended earnings/EV-EBITDA view with dividend support, tempered by patent-cliff, pricing, and leverage risks; mixed evidence supports HOLD. No sell-side targets used; not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Model Recommendation v2",
          "risks": [
            "Pipeline failures or delays",
            "Faster generic or biosimilar erosion",
            "US pricing and IRA pressure",
            "Higher leverage reduces flexibility"
          ],
          "ticker": "BMY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Cash flow stays solid while newer brands partly offset LOE pressure.",
              "target_price": 62
            },
            "bear": {
              "prob": 0.25,
              "notes": "Legacy erosion and weak pipeline execution drive de-rating.",
              "target_price": 50
            },
            "bull": {
              "prob": 0.25,
              "notes": "Pipeline wins and launch traction support modest re-rating.",
              "target_price": 72
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.082,
            "revenue_cagr_3y": 0.012,
            "terminal_multiple": 8.8,
            "ebit_margin_target": 0.34
          },
          "key_drivers": [
            {
              "driver": "New product uptake",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Revlimid generic erosion",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Eliquis franchise durability",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Opdivo growth and labels",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Margin discipline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt reduction pace",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pipeline readouts",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Drug-pricing pressure",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Used snapshot quote/fundamentals exactly. 12M target is a blended earnings/EV-EBITDA view with dividend support, tempered by patent-cliff, pricing, and leverage risks; mixed evidence supports HOLD. No sell-side targets used; not investment advice.",
          "current_price": 59.2,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Forward valuation looks inexpensive for a large-cap pharma franchise.",
            "Strong cash flow and dividend provide downside support.",
            "Revlimid erosion still offsets much of newer product growth.",
            "Pipeline and launches can stabilize revenue, but visibility is mixed.",
            "Leverage and patent-cliff risk limit multiple expansion."
          ],
          "target_price_6m": 60.9,
          "target_price_12m": 62
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0e0cce91f0a89a720069d756a889e48196ae50ac13c457f35b",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 26391,
        "createdAt": "2026-04-09T05:19:50.495Z",
        "usage": {
          "inputTokens": 2548,
          "outputTokens": 1468,
          "costUsd": 0.025011
        }
      },
      {
        "id": "cmnr12ktg02gwp6585uipd4t2",
        "runId": "cmnr12kte02gsp658db6tryyl",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Analyst Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"BMY\",\n  \"currency\": \"USD\",\n  \"current_price\": 59.2,\n  \"target_price_6m\": 63,\n  \"target_price_12m\": 70,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Eliquis and Opdivo sustain strong cash flows\",\n    \"Revlimid generics erode revenue base\",\n    \"Oncology pipeline offers future growth\",\n    \"Low valuation and high yield support stock\",\n    \"High debt requires careful capital allocation\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Eliquis/Opdivo revenue\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Revlimid patent expiration\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"New product launches\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Debt levels and interest costs\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Cash flow generation\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Forward PE valuation\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Pipeline success rate\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competition in key markets\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Patent litigation outcomes\",\n    \"Clinical development failures\",\n    \"Rising competition from biosimilars\",\n    \"Macroeconomic impact on drug pricing\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.035,\n    \"ebit_margin_target\": 0.3,\n    \"wacc\": 0.09,\n    \"terminal_multiple\": 12\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 48,\n      \"prob\": 0.3,\n      \"notes\": \"Accelerated erosion of key products and pipeline delays.\"\n    },\n    \"base\": {\n      \"target_price\": 70,\n      \"prob\": 0.5,\n      \"notes\": \"Moderate growth from new launches offsetting patent cliffs.\"\n    },\n    \"bull\": {\n      \"target_price\": 88,\n      \"prob\": 0.2,\n      \"notes\": \"Strong pipeline delivery and margin expansion.\"\n    }\n  },\n  \"method_notes\": \"DCF valuation anchored on 3.5% 3Y revenue CAGR to support target EBIT margin of 30%, discounted at 9% WACC with 12x terminal multiple. Balanced bull/bear risks around patent cliffs and pipeline; 18% upside supports BUY. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Analyst Model",
          "risks": [
            "Patent litigation outcomes",
            "Clinical development failures",
            "Rising competition from biosimilars",
            "Macroeconomic impact on drug pricing"
          ],
          "ticker": "BMY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Moderate growth from new launches offsetting patent cliffs.",
              "target_price": 70
            },
            "bear": {
              "prob": 0.3,
              "notes": "Accelerated erosion of key products and pipeline delays.",
              "target_price": 48
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong pipeline delivery and margin expansion.",
              "target_price": 88
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.035,
            "terminal_multiple": 12,
            "ebit_margin_target": 0.3
          },
          "key_drivers": [
            {
              "driver": "Eliquis/Opdivo revenue",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Revlimid patent expiration",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "New product launches",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt levels and interest costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Cash flow generation",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Forward PE valuation",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline success rate",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competition in key markets",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF valuation anchored on 3.5% 3Y revenue CAGR to support target EBIT margin of 30%, discounted at 9% WACC with 12x terminal multiple. Balanced bull/bear risks around patent cliffs and pipeline; 18% upside supports BUY. Not investment advice.",
          "current_price": 59.2,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Eliquis and Opdivo sustain strong cash flows",
            "Revlimid generics erode revenue base",
            "Oncology pipeline offers future growth",
            "Low valuation and high yield support stock",
            "High debt requires careful capital allocation"
          ],
          "target_price_6m": 63,
          "target_price_12m": 70
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "063c6a40-9c29-9aef-9a08-ca3e0532651c",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 19926,
        "createdAt": "2026-04-09T05:19:50.495Z",
        "usage": {
          "inputTokens": 2872,
          "outputTokens": 3793,
          "costUsd": 0.065511
        }
      }
    ]
  }
}